Bijal Mehta
Vascular Neurology · Buffalo, NYNPI 1144535774
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $939 of the $1,432 with a category attached, or 65.6%. Janssen Research & Development, LLC accounts for 89.5% of it on its own, with 1 other manufacturer making up the rest.
Across 13 payments — averaging $110.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- Biogen$150
Across 126 payments — averaging $10,879 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$638K
- Genentech, Inc.$510K
- Sanofi$131K
- Janssen Research & Development, LLC$45K
- E.r. Squibb & Sons, L.L.C.$27K
- Osmotica Pharmaceutical Corp.$21K
What the payments were for
- Consulting fees$15010%
- Travel & lodging$93966%
- Food & beverage$34324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 12 | $1,282 |
| Biogen | 1 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$150
How this compares
$1,432 in reported general payments places this provider in the 60th percentile of 74 vascular neurology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TysabriNatalizumab | 12 | $93,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTysabri | $150 | $93,40212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 74 vascular neurology providers in New York.
Other vascular neurology in Buffalo
- Amit KandelBuffalo$425
- Emma CiafaloniRochester$569K
- Koto IshidaNew York$63K
- Charles ThorntonRochester$40K
- Richard JungBay Shore$38K
- Sammy PishanidarFlushing$14K
- Alrabi TawilRochester$9K
- Ina Teron-MolinaRichmond Hill$8K
- Takamasa HigashimoriRochester$7K
- Jeremy LiffGreenvale$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.